[BioTimes] Medical aesthetics brand ERBELLA announced on June 17 that it participated in AMUSE 2026 (Aesthetic Medical Updates & Scientific Exhibition), an international aesthetic medicine congress held in Indonesia from June 12 to 14. At the event, ERBELLA operated its own exhibition booth and introduced ERBELLA AQ and the ERBELLA Skin Booster Collection to local medical professionals and global buyers. Following its recent pre-launch activities in Vietnam earlier this month, ERBELLA is continuing its step-by-step global expansion strategy, with a particular focus on Southeast Asian markets including Indonesia. Now in its third year, AMUSE is a scientific congress where aesthetic medicine professionals from various specialties, including dermatology and plastic surgery, gather to share the latest industry trends, clinical insights, and treatment techniques. Through its participation, ERBELLA expanded its engagement with regional buyers and strengthened its local business network in Indonesia’s rapidly growing medical aesthetics market. During the congress, ERBELLA held meetings with leading Indonesian physicians and local distributors to discuss potential partnerships and distribution channel development. Following its initial product introduction through collaboration with a local partner in Vietnam, the company further broadened its regional presence through its participation in Indonesia, establishing a foundation for expansion into neighboring markets. Moving forward, ERBELLA plans to refine its market-entry strategy for each country based on local market trends and the needs of healthcare professionals identified during the event. In addition, the company intends to develop a range of educational initiatives—including scientific exchanges with local KOLs, master classes, and hands-on workshops—to build a sustainable brand presence in Southeast Asia beyond simply supplying products. A representative from the MA Division of USCarePharm commented: “Following our first introduction in Vietnam, AMUSE 2026 provided an excellent opportunity to directly understand the trends of the Southeast Asian market and the needs of local healthcare professionals. We will thoroughly prepare product portfolios and educational support tailored to each country's market characteristics, with the goal of becoming a trusted global brand that grows together with our local partners.” Source: BioTimes Reporter: Jinju Choi (news@biotimes.co.kr)

2026.06.17

[BioTimes] USCAREPHARM Co., Ltd. (CEO Seokjin Song), a company specializing in bio-medical aesthetics, announced on the 17th that it has been finally selected as a 2026 Global IP (Intellectual Property) Star Company, a program organized by the Korean Intellectual Property Office and Gyeonggi Province. The Global IP Star Company program selects promising small and medium-sized enterprises with strong export growth potential and provides them with customized, comprehensive intellectual property-based support over a three-year period. USCAREPHARM was selected in recognition of its technological capabilities in biodegradable polymer-based medical devices and the global expansion potential of its proprietary brands. USCAREPHARM is an R&D-driven company that has developed differentiated products in the fields of medical aesthetics and bio-healthcare based on its experience in pharmaceutical and healthcare research and development. Leveraging its accumulated core technologies, including ORTE® biodegradable microparticle technology and its development experience with Curing Hyaluronic Acid®, a solid cross-linked hyaluronic acid material, the company has continued to commercialize and market its technologies through its medical aesthetics brand ERBELLA®. Recently, USCAREPHARM has achieved tangible results in overseas markets such as Vietnam and Saudi Arabia, while also stepping up its entry into the South American market, further accelerating its global business expansion. Through this latest selection, the company plans to strengthen its IP competitiveness by further accelerating overseas patent filings and securing trademark and design rights. As a result of this selection, USCAREPHARM will receive intensive support over the next three years for securing intellectual property rights, including overseas patent applications and brand and design development. Based on this support, the company plans to strengthen its technological protection barriers as it expands into global aesthetics markets such as North America and Europe. A representative from USCAREPHARM stated, “Being selected as a Global IP Star Company is a meaningful achievement that officially recognizes our technological capabilities and global growth potential.” The representative added, “Moving forward, we will build on a strong intellectual property portfolio to grow into an innovative company leading the global bio-medical aesthetics market.”

2026.04.22 14:30

USCAREPHARM announced on the 25th that it has signed an exclusive distribution agreement in Vietnam for the ERBELLA Skin Booster Collection with REGENIX, a local Vietnamese company specializing in the distribution of medical devices. Under this agreement, REGENIX has secured exclusive distribution rights for ERBELLA Skin Booster products throughout Vietnam. Beyond simple product supply, the two companies have agreed to build a comprehensive partnership that includes local marketing, medical practitioner training, and the development of treatment protocols. The ERBELLA Skin Booster Collection offers a specialized product portfolio tailored to each indication, including brightening, hydration, anti-aging, and acne care. The products can be used in combination with drug delivery devices to maximize treatment efficacy, and customized treatment protocols can be designed according to each patient’s skin condition and needs. According to the company, local medical professionals in Vietnam have shown strong interest in the product lineup, which is capable of addressing the country’s diverse skin types and climate conditions. USCAREPHARM and REGENIX plan to roll out training and marketing activities for Vietnamese medical professionals in phases. They intend to hold regular seminars and hands-on workshops in major cities while expanding their local medical network. USCAREPHARM also plans to position Vietnam as a strategic hub for its Southeast Asian aesthetics business and pursue step-by-step expansion into neighboring countries. A representative from USCAREPHARM’s MA Division stated, “Vietnam is a key market where demand for aesthetic procedures is rapidly increasing. Through a long-term partnership with REGENIX, we will expand the presence of ERBELLA Skin Booster in the local market.” The representative added, “Rather than focusing solely on product exports, we aim to build a successful model in Vietnam based on a partnership that includes education and marketing, and use this as a foundation to expand our business across Southeast Asia.”

2026.03.25 17:47